Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Institut Curie: Clinical Trials & FDA Approval Profile

Institut Curie (Global / Institutional) sponsors 16 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 9 active protocols (6 recruiting now), 2 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)31.3%
Median Closed Enrollment vs National (145 pts)33 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Institut Curie
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)16
Active Pipeline (Recruiting Now)9 (6)
Completed vs Stopped Early2 / 5 (31.3%)
Median Closed Actual Enrollment33 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Institut Curie
Hospital Research SiteLocationShared Protocols
Institut CurieParis, Île-de-France Region13
Centre Oscar LambretLille, Hauts-de-France3
Institut Paoli-CalmettesMarseille2

Explore interactive annual charts and M&A subsidiary rollups in the Institut Curie Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI